FDA Approves mFLUSIVA, the First mRNA-Based Seasonal Influenza Vaccine for Adults Aged 50 and Older

The U.S. Food and Drug Administration (FDA) has approved mFLUSIVA, the first mRNA-based seasonal influenza vaccine, for adults aged 50 years and older. This vaccine offers stronger protection against seasonal influenza compared to standard flu shots, demonstrating 26.6% higher protection against laboratory-confirmed influenza in a large Phase 3 clinical trial. Researchers believe mRNA technology could enhance future flu vaccines by allowing faster adaptation to evolving viruses.